There are 2137 resources available
1355P - Value of rebiopsy in advanced epidermal growth factor receptor mutated non-small cell lung cancer: Real-world data
Presenter: Rita Conde
Session: E-Poster Display
Resources:
Abstract
1356P - Disease monitoring and TKI resistance mutations of EGFR mutation-positive NSCLC patients via circulating tumour DNA
Presenter: Christine Ju
Session: E-Poster Display
Resources:
Abstract
1357P - Outcomes of treated patients with EGFR-mutated advanced or metastatic non-small cell lung cancer harboring exon 19 deletions or L858R substitution (Exon 21) mutations: A systematic literature review
Presenter: Katherine Winfree
Session: E-Poster Display
Resources:
Abstract
1358P - Efficacy and toxicity of combined inhibition of EGFR and VEGFR in advanced non-small cell lung cancer patients harboring activating EGFR mutations: A systematic review and meta-analysis
Presenter: Jasna Deluce
Session: E-Poster Display
Resources:
Abstract
1359P - Clinical characteristics of advanced NSCLC patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations
Presenter: Sameh Daher
Session: E-Poster Display
Resources:
Abstract
1360P - Identification of epidermal growth factor receptor (EGFR) fusions in a large Chinese lung cancer population
Presenter: Dongyuan Zhu
Session: E-Poster Display
Resources:
Abstract
1361P - Determination of ALK rearrangements in non-small cell lung cancer: Clinical and economic impact of current practice in Spain
Presenter: Luis Cabezón Gutiérrez
Session: E-Poster Display
Resources:
Abstract
1362P - Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
Presenter: Dimitrios Tomaras
Session: E-Poster Display
Resources:
Abstract
1363P - Real-world treatment patterns of patients with locally advanced/metastatic EGFRm NSCLC in Belgium (REVEAL)
Presenter: Kristof Cuppens
Session: E-Poster Display
Resources:
Abstract
1364P - Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
Presenter: Frank Griesinger
Session: E-Poster Display
Resources:
Abstract